Shanghai Pharmaceuticals' Subsidiary Gets Registration Certificate for Pyridostigmine Oral Solution

MT Newswires Live01-12

Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its pyridostigmine oral solution, according to a Shanghai bourse filing on Saturday.

The pharmaceutical company's Hong Kong shares slipped less than 1% during Monday's trade.

The drug is used for the treatment of myasthenia gravis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment